 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Hormone replacement therapy increases the risk of breast cancer in BRCA mutation carriers over 45 years old by 3 times!

Eur J Cancer: Hormone replacement therapy increases the risk of breast cancer in BRCA mutation carriers over 45 years old by 3 times!

 Last Update: 2021-03-30
 Source: Internet
 Author: User

Tags

1 3 simplified

beni johnson cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

BRCA1/BRCA2 mutation carriers usually undergo salpingo-oophorectomy (RRSO) before natural menopause to reduce the risk of ovarian cancer and fallopian tube cancer, but this increases the use of hormone replacement therapy (HRT) problems.

Ovarian cancer

There is conflicting evidence regarding the impact of hormone replacement therapy on breast cancer (BC) risk; in addition, there are limited risk data based on age of exposure.

Breast cancer In the general population, HRT users have an increased risk of breast cancer (hazard ratio [HR]=1.

This study aims to assess the impact of short-term use of HRT on the risk of breast cancer in healthy people with BRCA1/2 mutations, focusing on the age at the time of HRT exposure.

The impact of short-term use of HRT on the risk of breast cancer in healthy people with BRCA1/2 mutations focuses on the age at the time of exposure to HRT.

The researchers conducted a retrospective cohort follow-up of 306 healthy people with BRCA1/2 mutations who received RRSO, with an average follow-up of 7.

Breast cancer incidence after RRSO

During follow-up, 36 carriers were diagnosed with breast cancer: 20 out of 148 carriers in the HRT group were diagnosed as breast cancer (13.

Among the population undergoing RRSO after the age of 45, the prevalence of breast cancer among HRT users was significantly higher than that of non-HRT users (OR=3.

Among BRCA1/BRCA2 mutation carriers, women over 45 years of age who use hormone replacement therapy for short-term after salpingo-oophorectomy have an increased risk of breast cancer by up to 3 times as much as 3 times

Original source:

Michaelson-Cohen Rachel, Gabizon-Peretz Shira, Armon Shunit et al.

org/10.
1016/j.
ejca.
2021.
02.
007" target="_blank" rel="noopener">Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.